Analysts predict that Intersect ENT Inc (NASDAQ:XENT) will report earnings of ($0.14) per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Intersect ENT’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.17). Intersect ENT reported earnings per share of ($0.11) in the same quarter last year, which would suggest a negative year-over-year growth rate of 27.3%. The company is expected to issue its next earnings report on Tuesday, February 26th.

On average, analysts expect that Intersect ENT will report full-year earnings of ($0.73) per share for the current financial year, with EPS estimates ranging from ($0.76) to ($0.68). For the next financial year, analysts anticipate that the firm will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.69) to ($0.31). Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow Intersect ENT.

Intersect ENT (NASDAQ:XENT) last released its earnings results on Monday, November 5th. The medical equipment provider reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. The firm had revenue of $24.70 million during the quarter, compared to the consensus estimate of $24.09 million. Intersect ENT had a negative return on equity of 17.62% and a negative net margin of 20.00%. The company’s revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.15) EPS.

Several analysts recently weighed in on XENT shares. Zacks Investment Research upgraded Intersect ENT from a “hold” rating to a “buy” rating and set a $30.00 price objective for the company in a research report on Wednesday, November 7th. Northland Securities restated a “hold” rating and set a $28.00 price objective on shares of Intersect ENT in a research report on Monday, November 5th. BidaskClub downgraded Intersect ENT from a “hold” rating to a “sell” rating in a research report on Wednesday, October 24th. ValuEngine upgraded Intersect ENT from a “hold” rating to a “buy” rating in a research report on Tuesday, October 2nd. Finally, BTIG Research restated a “hold” rating on shares of Intersect ENT in a research report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $37.17.

Shares of NASDAQ:XENT traded up $0.47 during trading on Wednesday, reaching $29.15. 113,759 shares of the company traded hands, compared to its average volume of 323,038. The company has a market cap of $907.49 million, a price-to-earnings ratio of -52.05 and a beta of 0.57. Intersect ENT has a 52 week low of $25.15 and a 52 week high of $42.95.

In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,833 shares of the company’s stock in a transaction dated Monday, October 8th. The stock was sold at an average price of $27.99, for a total value of $359,195.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lisa D. Earnhardt sold 20,000 shares of the company’s stock in a transaction dated Thursday, November 15th. The stock was sold at an average price of $30.01, for a total value of $600,200.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 85,666 shares of company stock valued at $2,505,926. Insiders own 5.90% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. increased its stake in shares of Intersect ENT by 10.1% in the first quarter. Principal Financial Group Inc. now owns 16,564 shares of the medical equipment provider’s stock valued at $651,000 after buying an additional 1,524 shares during the period. UBS Group AG increased its stake in shares of Intersect ENT by 81.1% in the first quarter. UBS Group AG now owns 4,679 shares of the medical equipment provider’s stock valued at $184,000 after buying an additional 2,096 shares during the period. Strs Ohio increased its stake in shares of Intersect ENT by 9.7% in the second quarter. Strs Ohio now owns 25,900 shares of the medical equipment provider’s stock valued at $969,000 after buying an additional 2,300 shares during the period. Man Group plc increased its stake in shares of Intersect ENT by 32.2% in the third quarter. Man Group plc now owns 10,289 shares of the medical equipment provider’s stock valued at $296,000 after buying an additional 2,509 shares during the period. Finally, MetLife Investment Advisors LLC increased its stake in shares of Intersect ENT by 22.2% in the second quarter. MetLife Investment Advisors LLC now owns 13,971 shares of the medical equipment provider’s stock valued at $523,000 after buying an additional 2,537 shares during the period. 79.59% of the stock is owned by institutional investors.

Intersect ENT Company Profile

Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.

Featured Story: How to Profit and Limit Losses With Stop Orders

Get a free copy of the Zacks research report on Intersect ENT (XENT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.